A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 11, 2012, Pages 1196-1198

  Ewert, Ralf ^a   Halank, Michael ^b   Bruch, Leonhard ^c   Ghofrani, Hossein Ardeschir ^d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNFALLKRANKENHAUS BERLIN   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ILOPROST; PROSTANOID; SILDENAFIL; TREPROSTINIL;

DEVICE SAFETY; DRUG DOSE TITRATION; DRUG SAFETY; IMPLANTABLE PUMP; LETTER; MEDICAL DEVICE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 84870474457     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.186.11.1196     Document Type: Letter

References (18)

1. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL; Scientific Leadership Council of the Pulmonary Hypertension Association. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008;160:5-9.
2. Ivy DD, Calderbank M, Wagner BD, Dolan S, Nyquist AC, Wade M, Nickels WM, Doran AK. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol 2009;30:823-829.
3. Dickinson MG, Schölvinck EH, Boonstra A, Vonk-Noordegraaf A, Snijder RJ, Berger RM. Low complication rates with totally implantable access port use in epoprostenol treatment of pulmonary hypertension. J Heart Lung Transplant 2009;28:273-279.
4. O'Callaghan DS, Moutet A, Jais X, Yaici A, Savale L, Natali D, Parent F, Simonneau G, Humbert M, Doucet-Populaire F, et al. Catheter related infections in pulmonary hypertension patients treated by continuous intravenous epoprostenol: experience of the French referral centre. Am J Respir Crit Care Med 2010;181:A3337.
5. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States 2003-2006. MMWR Morb Mortal Wkly Rep 2007; 56:170-172.
6. Dario A, Scamoni C, Picano M, Fortini G, Cuffari S, Tomei G. The infection risk of intrathecal drug infusion pumps after multiple refill procedures. Neuromodulation 2005;8:36-39.
7. Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996;85:458-467.
8. Naumann C, Erdine S, Koulousakis A, Van Buyten JP, Schuchard M. Drug adverse events and system complications of intrathecal opioid delivery for pain: origins, detection, manifestations, and management. Neuromodulation 1999;2:92-107.
9. Hoeper MM, Gall H, Seyfarth HJ, Halank M, Ghofrani HA, Winkler J, Golpon H, Olsson KM, Nickel N, Opitz C, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009;34:132-137.
10. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-299.
11. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, Barst RJ. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006;129:683-688.
12. Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, Barst RJ. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;2005:1586-1589.
13. Sitbon O, Manes A, Jais X, Pallazini M, Humbert M, Presotto L, Paillette L, Zaccardelli D, Davis G, Jeffs R, et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2007;49:1-5.
14. Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 2010;29:137-149.
15. Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J 2009;157:625-635.
16. McSwain CS, Benza R, Shapiro S. Dose proportionality of treprostinil sodium administrated by continuous subcutaneous and intravenous infusion. J Clin Pharmacol 2008;48:19-25.
17. Steringer-Mascherbauer R, Eder V, Huber C, Fuegger R, Wittrich S, Froschl U, Nesser HJ. Transitioning from subcutaneous so intravenous treprostinil administered by the implantable infusion pump LenusPro(R): a single-center pilot study. Am J Respir Crit Care Med 2012;185:A4807.
18. Steringer-Mascherbauer R, Andreassen AK, Boonstra A, Bremer H, Hohenforst-Schmidt W, Jansa P, Kaehler CM, Krueger U, Rochat T, Speich R, et al. First multi-center long term experience and safety data of intravenous treprostinil administered by the implantable infusion pump Lenus Pro(R). Am J Respir Crit Care Med 2012;185:A4102.